Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial

European Neuropsychopharmacology

Volumn 7, Issue 2, 1997, Pages 125-137

  Beasley Jr , Charles M ^a   Hamilton, Susan H ^a   Crawford, Ann Marie ^a   Dellva, Mary Anne ^a   Tollefson, Gary D ^a   Tran, Pierre V ^a   Blin, Olivier ^b   Beuzen, Jean Noel ^a  

^a ELI LILLY AND COMPANY   (United States)

^b TIMONE HOSPITAL   (France)

Author keywords

Acute; Atypical antipsychotic; Double blind; Extrapyramidal syndromes; Haloperidol; Olanzapine; Prolactin; Schizophrenia

Indexed keywords

HALOPERIDOL; OLANZAPINE; PROLACTIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; SCHIZOPHRENIA;

EID: 0342872086     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(96)00392-6     Document Type: Article

References (28)

1. Alvir, J.M., Lieberman, J.A., Safferman, A.Z., Schwimmer, J.L. and Schaaf, J.A. (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med. 329, 162-167.
2. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders. 3rd ed, revised. American Psychiatric Association, Washington, DC.
3. Baldwin, D.S. and Montgomery, S.A. (1995) First clinical experience with olanzapine (LY170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. Int. Clin. Psychopharmacol. 10, 239-244.
4. Barnes, T.R. (1989) A rating scale for drug-induced akathisia. Br. J. Psych. 154, 672-676.
5. Bauer, D. and Gaertner, M.J. (1983) Wirkungen der neuroleptika auf die leberfunktion das blutbildende system, den blutdruck und die temperaturregulation. Pharmacopsychiatry 16, 23-29.
6. Beasley, C.M., Tollefson G., Tran, P, Satterlee, W., Sanger T., Hamilton S. and the Olanzapine HGAD Study Group (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14, 105-118.
7. Casey, D.E. (1989) Clozapine: antipsychotic-induced EPS and tardive dyskinesia. Psychopharmacology 99, S47-S53.
8. Chouinard, G., Jones, B., Remington, G., et al. (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients. J. Clin. Psychopharmacol. 13, 25-40.
9. Davies, L.M. and Drummond, M.F. (1994) Economics and schizophrenia: the real cost. Br. J. Psychiatry 165 (suppl 25), 18-21.
10. Gaertner, H.J., Fischer, E. and Hoss, J. (1989) Side effects of clozapine. Psychopharmacology 99, S97-S100.
11. Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology. Revised ed. US Dept of Health, Education and Welfare, Bethesda, MD.
12. Hemrick-Luecke, S.K., Bymaster, F.P., Falcone, J.F., Moore, N.A., Tye, N.C. and Fuller, R.W (1993) Effect of olanzapine on rat brain receptor binding, acetylcholine levels and monoamine turnover. Presented at the 10th Annual Society for Neuroscience Meeting, Indianapolis Chapter, and the 23rd Annual Society for Neuroscience Meeting, May 21 and November 7-12, Indianapolis, IN and Washington, DC.
13. Kane, J.M., Cooper, T.B., Sachar, E.J., Halpern, F.S. and Bailine, S. (1981) Clozapine: plasma levels and prolactin response. Psychopharmacology 73, 184-187.
14. Kane, J., Honigfeld, G., Singer, J., Meltzer, H. and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry 45, 789-796.
15. Kay, S.R., Opler, L.A. and Fiszbein, A. (1992) Positive and Negative Syndrome Scale (PANSS) Manual. Multi-Health Systems, Inc, North Tonawanda, NY.
16. Leppig, M., Bosch, B., Naber, D. and Hippius, H. (1989) Clozapine in the treatment of 121 out-patients. Psychopharmacology 99, S77-S79.
17. Marder, S.R. and Meibach, R.C. (1994) Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 151, 825-835.
18. Meltzer, H.Y., Goode, D.J., Schyve, P.M., Young, M. and Fang, V.S. (1979) Effect of clozapine on human serum prolactin levels. Am. J. Psychiatry 136, 1550-1555.
19. Moore, N.A., Calligaro, D.O., Wong, T.D., Bymaster, F. and Tye, N.C. (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr. Opin. Invest. Drugs 2, 281-293.
20. Moore, N.A., Rees, G., Sanger, G. and Tye, N.C. (1994) Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav. Pharmacol. 5, 196-202.
21. Moore, N.A., Tye, N.C., Axton, M.S. and Risius, F.C. (1992) The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J. Pharmacol. Exp. Ther. 262, 545-551.
22. Naber, D., Leppig, M., Grohmann, R. and Hippius, H. (1989) Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients. Psychopharmacology 99, S73-S76.
23. SAS Institute Inc. (1990) SAS/STAT User's Guide Vol 1 and 2, 4th ed, 6th version. SAS Institute Inc, Cary, NC.
24. Seeman, P. and Van Thol, H.H.M. (1993) Dopamine receptor pharmacology. Curr. Opin. Neurol. Neurosurg. 6, 602-608.
25. Simpson, G.M. and Angus, J.W. (1970) A rating scale for extrapyramidal side effects. Acta. Psychiatr. Scand. Suppl. 212, 11-19.
26. Stockton, M.E. and Rasmussen, K. (1996) Electrophysiological effects of olanzapine, a novel atypical antypsychotic on A9 and A10 dopamine neurons. Neuropsychopharmacology 14, 97-104.
27. Tye, N.C., Moore, N.A., Rees, G., Sanger, G., Calligaro, D.O. and Beasley, C.M. (1992) Preclinical pharmacology of olanzapine: a novel 'atypical' antipsychotic agent. Presented at the Second International Conference on Schizophrenia, July 18-22, Vancouver, BC.
28. Wong, D.T., Moore, N.A., Calligaro, O., Bymaster, F.P. and Seeman, P. (1993) The preclinical pharmacology of olanzapine, a novel antipsychotic. Presented at the Ninth World Congress of Psychiatry, June 6-12, Rio de Janeiro, Brazil.